

New Drug Epinephrine Nasal Spray (*Neffy*)



Why it m Injectable

Why it matters:

Injectable epinephrine devices have been the go-to for treating severe allergic reactions including anaphylaxis. Neffy is now the first epinephrine NASAL SPRAY approved for this use.

What else to know:

Continue to recommend an emergency epinephrine device based on patient preference, availability, and cost. The "best" choice is the one that patients and their caregivers are willing and able to use correctly.

Manufacturer	ARS Pharma
FDA approved use	 Epinephrine 2 mg nasal spray is indicated to treat severe allergic reactions, including anaphylaxis, in patients who weigh 30 kg (66 lb) or more. A 1 mg dose for patients who weigh 15 to 30 kg (33 to 66 lb) is being reviewed by FDA.
FDA approval date	August 2024
Anticipated availability	September 2024
Dosage and administration	 Each device contains 1 dose. One spray should be administered into one nostril for symptoms of a severe allergic reaction. A second dose may given in the SAME nostril 5 minutes after the first dose, if needed.
Storage requirements	 Patients should store epinephrine nasal spray at room temperature. Storage at temperatures up to 122°F is allowed for a few days. Epinephrine nasal spray has a shelf life of 30 months from date of manufacture.
Prescribing information	https://www.ars-pharma.com/wp-content/uploads/pdf/Prescribing_Information.pdf

References:

Ellis AK, Casale TB, Kaliner M, et al. Development of neffy, an Epinephrine Nasal Spray, for Severe Allergic Reactions. <u>Pharmaceutics.</u> 2024 Jun 14;16(6):811.

Casale TB, Ellis AK, Nowak-Wegrzyn A, et al. Pharmacokinetics/pharmacodynamics of epinephrine after single and repeat administration of neffy, EpiPen, and manual intramuscular injection. <u>J Allergy Clin Immunol. 2023 Dec;152(6):1587-1596.</u>

Article, <u>Explain How Epinephrine Nasal Spray Compares to Injectables</u>. Pharmacist's Letter/Pharmacy Technician's Letter/Prescriber Insights. October 2024. [401001] For nearly 40 years, our editors have distilled primary literature into unbiased, evidence-based recommendations with 0% pharma sponsorship. Learn more